Tacrolimus 99% Tacrolimus Pharmaceutical Ingredient 104987-11-3 Antifungal
Posted on

Model NO.: 104987-11-3
Shipment: DHL, FedEx, EMS, TNT, etc.
Assay: 99%Min
Discount: Yes
Others: Reshipping Policy
Export Markets: Global
Delivery Time: 5-7 Days
Trademark: YC
Transport Package: Foil Bag/Tin
Specification: white powder
Origin: China
HS Code: 4202119090
Model NO.: 104987-11-3
Shipment: DHL, FedEx, EMS, TNT, etc.
Assay: 99%Min
Discount: Yes
Others: Reshipping Policy
Export Markets: Global
Delivery Time: 5-7 Days
Trademark: YC
Transport Package: Foil Bag/Tin
Specification: white powder
Origin: China
HS Code: 4202119090
Tacrolimus

Tacrolimus CAS: 104987-11-3 
Tacrolimus MF: C44H69NO12 
Tacrolimus MW: 804.02 
Tacrolimus mp  113-115°C 
Tacrolimus storage temp.  ?20°C 
Tacrolimus solubility  DMSO: >3 mg/mL
Tacrolimus Chemical Properties White Crystalline Solid 
Tacrolimus Usage An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release. 
Tacrolimus Purity: 99%
Tacrolimus Usage: API
Tacrolimus Package: 1KG foil bag; 25Kg drum

Inteoduction:

Tacrolimus (also FK-506 or fujimycin, trade names Prograft, Advagraf, Protopic) is animmunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection. It achieves this by inhibiting the production of interleukin-2, a molecule that promotes the development and proliferation of T cells, which are vital to the body's learned (or adaptive) immune response. Tacrolimus is also used in the treatment of other T cell-mediated diseases such as eczema (for which it is applied to the skin in a medicated ointment), severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease, Kimura's disease, and the skin condition vitiligo.
Chemically it is a 23-membered macrolide lactone that was first discovered in 1987 from the fermentation broth of a Japanese soil sample that contained the bacterium Streptomyces tsukubaensis.

Usage:

It has similar immunosuppressive properties to ciclosporin, but is much more potent. Immunosuppression with tacrolimus was associated with a significantly lower rate of acute rejection compared with ciclosporin-based immunosuppression (30.7% vs 46.4%) in one study. Clinical outcome is better with tacrolimus than with ciclosporin during the first year of liver transplantation. Long-term outcome has not been improved to the same extent. Tacrolimus is normally prescribed as part of a post-transplant cocktail including steroids, mycophenolate, and IL-2 receptor inhibitors such as basiliximab. Dosages are titrated to target blood levels.

Mechanism of action:

Tacrolimus is a macrolide calcineurin inhibitor. In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. Calcineurin then dephosphorylates the transcription factor nuclear factor of activated T-cells (NF-AT), which moves to the nucleus of the T-cell and increases the activity of genes coding for IL-2 and related cytokines. Tacrolimus prevents the dephosphorylation of NF-AT.
In detail, tacrolimus reduces peptidylprolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein), creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin, thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription. Although this activity is similar to that of ciclosporin, the incidence of acute rejection is reduced by tacrolimus use over ciclosporin use. Although short-term immunosuppression concerning patient and graft survival is found to be similar between the two drugs, tacrolimus results in a more favorable lipid profile, and this may have important long-term implications given the prognostic influence of rejection on graft survival.


--------------------------------  Additional Information  -------------------------------
Place of origin : China
Brand : YC
Certificate : ISO9001:2008, KOSHER, GMP, SGS
Minimum order quantity : 1 kg
Production capacity : 1000 Kilograms/Month

--------------------------------  Delivery Information  ---------------------------------
Packing : Foil bag/tin or as your request
Payment : T/T, Western Union, MoneyGram, BitCoin
Port : Shanghai, Shenzhen, Hongkong
Shipment method : EMS, DHL, FeDex, UPS, etc
Leading  time : Within 24 hours after payment
Delivery time : Within 6 business days after payment (door to door service)

--------------------------------  Our Competitive Advantages  ---------------------------
1.Please let me know the items you are looking for, quantity, and the destination country.
2. We send the detailed price of our product and offer the suitable shipping method for your reference.
3. You confirm the order and pay money 100% in advance and send us the detailed address.
4.We will pack your parcel and arrange to shipment according to your requirements         
5.Once parcel is sent,I will offer you parcel's picture,tracking number and tracking website.
6.After you receiving parcel,we will offer you best after-sale.

It's Amy, hope to cooperate with you, be your reliable supplier and build a long friendly relationship with you. You are welcomed to contact me at any time. Tacrolimus

Tacrolimus CAS: 104987-11-3 
Tacrolimus MF: C44H69NO12 
Tacrolimus MW: 804.02 
Tacrolimus mp  113-115°C 
Tacrolimus storage temp.  ?20°C 
Tacrolimus solubility  DMSO: >3 mg/mL
Tacrolimus Chemical Properties White Crystalline Solid 
Tacrolimus Usage An immunosuppressant that blocks T cell proliferation in vitro by inhibiting the generation of several lymphokines, especially IL-2. Shown to inhibit the activity of FK-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum Ca+2 release. 
Tacrolimus Purity: 99%
Tacrolimus Usage: API
Tacrolimus Package: 1KG foil bag; 25Kg drum

Inteoduction:

Tacrolimus (also FK-506 or fujimycin, trade names Prograft, Advagraf, Protopic) is animmunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection. It achieves this by inhibiting the production of interleukin-2, a molecule that promotes the development and proliferation of T cells, which are vital to the body's learned (or adaptive) immune response. Tacrolimus is also used in the treatment of other T cell-mediated diseases such as eczema (for which it is applied to the skin in a medicated ointment), severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease, Kimura's disease, and the skin condition vitiligo.
Chemically it is a 23-membered macrolide lactone that was first discovered in 1987 from the fermentation broth of a Japanese soil sample that contained the bacterium Streptomyces tsukubaensis.

Usage:

It has similar immunosuppressive properties to ciclosporin, but is much more potent. Immunosuppression with tacrolimus was associated with a significantly lower rate of acute rejection compared with ciclosporin-based immunosuppression (30.7% vs 46.4%) in one study. Clinical outcome is better with tacrolimus than with ciclosporin during the first year of liver transplantation. Long-term outcome has not been improved to the same extent. Tacrolimus is normally prescribed as part of a post-transplant cocktail including steroids, mycophenolate, and IL-2 receptor inhibitors such as basiliximab. Dosages are titrated to target blood levels.

Mechanism of action:

Tacrolimus is a macrolide calcineurin inhibitor. In T-cells, activation of the T-cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin. Calcineurin then dephosphorylates the transcription factor nuclear factor of activated T-cells (NF-AT), which moves to the nucleus of the T-cell and increases the activity of genes coding for IL-2 and related cytokines. Tacrolimus prevents the dephosphorylation of NF-AT.
In detail, tacrolimus reduces peptidylprolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein), creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin, thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription. Although this activity is similar to that of ciclosporin, the incidence of acute rejection is reduced by tacrolimus use over ciclosporin use. Although short-term immunosuppression concerning patient and graft survival is found to be similar between the two drugs, tacrolimus results in a more favorable lipid profile, and this may have important long-term implications given the prognostic influence of rejection on graft survival.


--------------------------------  Additional Information  -------------------------------
Place of origin : China
Brand : YC
Certificate : ISO9001:2008, KOSHER, GMP, SGS
Minimum order quantity : 1 kg
Production capacity : 1000 Kilograms/Month

--------------------------------  Delivery Information  ---------------------------------
Packing : Foil bag/tin or as your request
Payment : T/T, Western Union, MoneyGram, BitCoin
Port : Shanghai, Shenzhen, Hongkong
Shipment method : EMS, DHL, FeDex, UPS, etc
Leading  time : Within 24 hours after payment
Delivery time : Within 6 business days after payment (door to door service)

--------------------------------  Our Competitive Advantages  ---------------------------
1.Please let me know the items you are looking for, quantity, and the destination country.
2. We send the detailed price of our product and offer the suitable shipping method for your reference.
3. You confirm the order and pay money 100% in advance and send us the detailed address.
4.We will pack your parcel and arrange to shipment according to your requirements         
5.Once parcel is sent,I will offer you parcel's picture,tracking number and tracking website.
6.After you receiving parcel,we will offer you best after-sale.

It's Amy, hope to cooperate with you, be your reliable supplier and build a long friendly relationship with you. You are welcomed to contact me at any time.